Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Cancer Vaccines01:30

Cancer Vaccines

972
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
972
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.5K
Overview
83.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Risk-Tiered Validation Framework for Artificial Intelligence in Drug Discovery: From Reproducibility to Clinical Translation.

International journal of molecular sciences·2026
Same author

Quantum Computing and Quantum Technologies in Drug Discovery and Therapeutics: Evidence, Benchmarking, and Translational Integration.

Drug design, development and therapy·2026
Same author

Therapeutic Alternatives to Recombinant Biologics: Mechanistic Framework, Clinical Evidence, and Selection Guidance.

Drug design, development and therapy·2026
Same author

Quantum mechanics in drug design: Progress, challenges, and future frontiers.

Communicative & integrative biology·2025
Same author

Artificial Intelligence in Small-Molecule Drug Discovery: A Critical Review of Methods, Applications, and Real-World Outcomes.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025).

Pharmaceutics·2025

Related Experiment Video

Updated: Jan 16, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Engineering Universal Cancer Immunity: Non-Tumor-Specific mRNA Vaccines Trigger Epitope Spreading in Cold Tumors.

Matthias Magoola1, Sarfaraz K Niazi2

  • 1DEI Biopharma, Kampala 10101, Uganda.

Vaccines
|September 27, 2025
PubMed
Summary

Universal mRNA cancer vaccines leverage innate immunity by activating pattern recognition receptors (PRRs) to induce epitope spreading. This approach transforms cold tumors into inflamed microenvironments, offering a cost-effective and rapidly deployable alternative to personalized neoantigen vaccines.

Keywords:
cancer immunotherapyepitope spreadingglobal health equityinnate immunitylipid nanoparticlesmRNA vaccinespolymer delivery systemstumor microenvironment

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

3.0K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.7K

Related Experiment Videos

Last Updated: Jan 16, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

3.0K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.7K

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Current cancer immunotherapy relies heavily on personalized neoantigen vaccines, which face significant manufacturing time and cost barriers.
  • Immunologically "cold" tumors resist T-cell infiltration and are less responsive to existing therapies.
  • There is a critical need for universal, broadly applicable cancer immunotherapy platforms.

Purpose of the Study:

  • To review a novel mRNA vaccine strategy utilizing non-tumor-specific antigens to activate innate immunity.
  • To explore how these vaccines convert "cold" tumors into inflamed, therapy-responsive microenvironments.
  • To assess the potential of this universal platform to overcome limitations of personalized cancer vaccines.

Main Methods:

  • The strategy employs mRNA encoding pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).
  • Innate immune activation is achieved through stimulation of multiple pattern recognition receptors (PRRs).
  • Delivery is optimized using lipid nanoparticles (LNPs) or polymer-based systems.

Main Results:

  • The vaccine platform induces epitope spreading, revealing cryptic tumor antigens and promoting T-cell responses.
  • It enhances responsiveness to checkpoint inhibitors and establishes durable antitumor memory.
  • Potential advantages include immediate availability, significant cost reduction, and scalability.

Conclusions:

  • This universal mRNA vaccine approach offers a paradigm shift from personalized neoantigen vaccines towards innate immune activation.
  • It has the potential to democratize access to advanced cancer treatments, particularly in low- and middle-income countries.
  • Further research is needed to address risks like cytokine release syndrome and potential autoimmunity.